The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...

参考文献：1.《中国银屑病诊疗指南（2023版）》2.中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版） [J] . 中华皮肤科杂志, 2023, 56(7) : 573-625. DOI: ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...

For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing ...

UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...